2.228USD+7.11%Mkt Cap: 11.62M USDP/E: —Last update: 2026-06-01
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develo…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap11.62M USD
Enterprise Value6.28M USD
Revenue (TTM)852.28K USD
Gross Profit-17.27M USD
Net Income (TTM)-21.46M USD
Revenue/Share0.6360 USD
Last Price2.228 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.40
PEG—
EV/EBITDA-0.29
EV/Revenue7.37
P/S12.59
P/B11.77
EPS (TTM)-13.82
EPS (Forward)-0.86
52W Range
0.96304% of range34.75
52W High34.75 USD
52W Low0.9630 USD
Profitability
Gross Margin0.00%
Oper. Margin-2523.43%
EBITDA Margin0.00%
Profit Margin-862.34%
ROE-561.15%
ROA-338.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.47M USD
CapEx (TTM)27.61K USD
FCF Margin-1302.45%
FCF Yield-95.54%
Net Debt-877.19K USD
Net Debt/EBITDA0.04
Balance Sheet
Debt/Equity0.22
Current Ratio1.06
Quick Ratio0.56
Book Value/Sh0.1750 USD
Cash/Share0.3660 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 25, 2020
Splits
Last Split1:25
Split DateJan 12, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)10.00 USD
Target Range10.00 USD – 10.00 USD
# Analysts2
Ownership
Shares Out.5.21M
Float3.47M
Insiders6.82%
Institutions9.85%
Short Interest
Short Ratio1.0d
Short % Float13.57%
Short % Out.13.56%
Shares Short470.94K
Short (prev mo.)277.56K
Technical
SMA 501.532 (+45.4%)
SMA 2007.638 (-70.8%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)9.99M
Avg Vol (10d)28.79M
Technical Indicators
RSI (14)51.7
MACD0.3422
MACD Signal0.2860
MACD Hist.+0.0562
BB Upper3.380 USD
BB Middle1.943 USD
BB Lower0.5064 USD
BB Width147.88%
ATR (14)0.5422 USD
Vol Ratio (20d)0.07x